DENVER--(BUSINESS WIRE)--June 12, 2006--Ceragenix Pharmaceuticals, Inc. today announced that in vitro research conducted at the Urology Clinic of the University of the Saarlandes, Germany has shown that one of Ceragenix’s lead compounds was able to significantly inhibit bladder cancer growth with minimal toxicity to normal cells. Ceragenix plans to test this compound for efficacy in an animal model.
